Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

By ··1 min read·3 sources

Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

PBMs are paid a share of the rebates they negotiate, which gives the middleman a financial stake in higher list prices. The three largest, Optum Rx, CVS Caremark and Express Scripts, processed about 80% of U.S. pharmacy claims in 2024 and 2025.

Enforcement so far has been light. The FTC sued all three in September 2024 over insulin rebates. Express Scripts settled on February 4, 2026, and Caremark on July 14, 2026. Neither settlement included a monetary penalty. Congress put PBM reform into the 2026 appropriations law, but Medicare's "delinking" of PBM pay from drug prices does not start until 2028.

Pfizer's Vyndamax shows what the system rewards. The drug brings in about 10% of Pfizer's revenue, with $6 billion in 2025 sales, at a list price of about $268,000 a year. BridgeBio's Attruby is cheaper. Yet Pfizer says Vyndamax still holds 75% of ATTR-CM prescription volume.

A Hunterbrook investigation into PBM rebate entities points to the reason: rebate structures favor the company big enough to offer the largest rebate. What Pfizer pays PBMs for Vyndamax's formulary position is confidential. Nobody outside those contracts can test whether its dominance is earned on clinical merit or bought. Patients whose cost-sharing is tied to list price pay for the difference.

Sources

  1. ftc.gov · ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artif…
  2. scienceworldreport.com · scienceworldreport.com/articles/62307/20260915/battle-against-pbms-over-getting-started.ht…
  3. hntrbrk.com · hntrbrk.com/investigations/pbmgpo

Cite this report

The Precedent. "Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.." October 2, 2026. https://theprecedent.org/article/vyndamax-made-6-billion-in-2025-with-a-cheaper-rival-on-the-market-the-rebate-sy